TickerFacts.

Accustem Sciences Inc. (ACUT): R&D Expense

Annual figures by period end, from SEC filings.

$281.0K
Year ended 2025-12-31
$355.7K
Trailing 12 months to 2026-06-30
+1.7%
3-year compound annual growth
2021-12-31: $73.3K2022-12-31: $266.9K2023-12-31: $139.7K2024-12-31: $138.3K2025-12-31: $281.0K$281.0K
2021-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$281.0K+103.2%2026-04-14, From 2025-01-01
2024-12-31$138.3K-1.0%2026-04-14, From 2024-01-01
2023-12-31$139.7K-47.7%2025-04-03, From 2023-01-01
2022-12-31$266.9K+264.0%2024-03-22, From 2022-01-01
2021-12-31$73.3Kn/a2023-02-15, From 2021-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Accustem Sciences Inc. (ACUT)2025-12-31$281.0K+103.2%
Semnur Pharmaceuticals, Inc. (SMNR)2025-12-31$2.55M+49.0%
Aspire Biopharma Holdings, Inc. (ASBP)2025-12-31$923.9K+540.0%
Alzamend Neuro, Inc. (ALZN)2026-04-30$3.63M+156.5%
NeuroSense Therapeutics Ltd. (NRSN)2025-12-31$6.23M+9.3%
Inhibitor Therapeutics, Inc. (INTI)2025-12-31$1.70M-3.5%
Vaccinex, Inc. (VCNX)2024-12-31$12.54M-24.3%
Ocean Biomedical, Inc. (OCEA)2024-12-31$26.0K-96.3%
Lipella Pharmaceuticals Inc. (LIPO)2024-12-31$3.61M+18.9%

Compare ACUT, SMNR, ASBP, ALZN side by side · Screen every company in Pharmaceutical Preparations ↗